{
  "id": 8194262,
  "title": "Sandoz Partners With MAbxience On Emicizumab Biosimilar; Pipeline Reaches 40 Assets",
  "url": "https://urgent.news/2026/09/18/sandoz-partners-with-mabxience-on-emicizumab-biosimilar-pipeline",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T05:58:08.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/sandoz-partners-mabxience-emicizumab-biosimilar-pipeline-reaches-40-assets"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Sandoz Group AG (SDZ.SW, SDZNY), a pharmaceutical company focused on affordable medicines, on Friday announced a collaboration with mAbxience for a proposed emicizumab biosimilar.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}